Granules India is currently trading at Rs. 137.40, up by 1.30 points or 0.96% from its previous closing of Rs. 136.10 on the BSE.
The scrip opened at Rs. 137.55 and has touched a high and low of Rs. 138.15 and Rs. 137.00 respectively. So far 18,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 164.45 on 01-Dec-2015 and a 52 week low of Rs. 75.55 on 12-Jun-2015.
Last one week high and low of the scrip stood at Rs. 138.15 and Rs. 125.90 respectively. The current market cap of the company is Rs. 2,977.00 crore.
The promoters holding in the company stood at 51.15% while Institutions and Non-Institutions held 7.59% and 41.26% respectively.
Granules India has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its Jeedimetla facility in December 2015.
The USFDA has acknowledged receipt of its responses sent on January 7 and March 28, 2016 on the observations issued by it for the Jeedimetla facility. The USFDA closed the matter and issued EIR for the Jeedimetla facility situated in the state of Telangana.
Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
